Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVELARDO, Fanny
dc.contributor.authorWATSON, Verity
dc.contributor.authorARWIDSON, Pierre
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALLA, Francois
dc.contributor.authorLUCHINI, Stephane
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSCHWARZINGER, Michael
dc.contributor.authorCOVAMAX STUDY, Group
dc.date.accessioned2022-01-17T12:41:17Z
dc.date.available2022-01-17T12:41:17Z
dc.date.issued2021-11-20
dc.identifier.issn2076-393X (Print) 2076-393X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124410
dc.description.abstractEnIt can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-19 vaccination intentions, although evidence is scarce. In this large and representative survey of 6007 adults aged 18-64 years and residing in France, 8.1% (95% CI, 7.5-8.8) reported a prior SARS-CoV-2 infection in December 2020, with regional variations according to an East-West gradient (p < 0.0001). In participants without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was substantial, including 41.3% (95% CI, 39.8-42.8) outright refusal of COVID-19 vaccination. Taking into account five characteristics of the first approved vaccines (efficacy, duration of immunity, safety, country of the vaccine manufacturer, and place of administration) as well as the initial setting of the mass vaccination campaign in France, COVID-19 vaccine acceptance would reach 43.6% (95% CI, 43.0-44.1) at best among working-age adults without prior SARS-CoV-2 infection. COVID-19 vaccine acceptance was primarily driven by vaccine characteristics, sociodemographic and attitudinal factors. Considering the region of residency as a proxy of the likelihood of getting infected, our study findings do not support the assumption that SARS-CoV-2 infection risk is associated with COVID-19 vaccine acceptance.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enSARS-CoV-2
dc.subject.enCOVID-19
dc.subject.enMass vaccination
dc.subject.enAnti-vaccination behavior
dc.subject.enVaccine hesitancy
dc.subject.enSurvey experiment
dc.subject.enDiscrete choice experiment
dc.subject.enFrance
dc.title.enRegional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/vaccines9111364en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34835295en_US
bordeaux.journalVaccinesen_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMRISPen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03528752
hal.version1
hal.date.transferred2022-01-17T12:41:20Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Vaccines&amp;rft.date=2021-11-20&amp;rft.volume=9&amp;rft.issue=11&amp;rft.eissn=2076-393X%20(Print)%202076-393X%20(Linking)&amp;rft.issn=2076-393X%20(Print)%202076-393X%20(Linking)&amp;rft.au=VELARDO,%20Fanny&amp;WATSON,%20Verity&amp;ARWIDSON,%20Pierre&amp;ALLA,%20Francois&amp;LUCHINI,%20Stephane&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée